The BC SKBR3 cells display an epithelial morphology in tissue culture and are a useful preclinical model to screen for new therapeutic agents which could overcome the drawback of resistance to HER2-targeted therapies, therefore these cells were considered for MTT tests. This evidence concerns the gene ERBB2 and breast cancer.